Novo Total Current Liabilities from 2010 to 2024
| NVO Stock | USD 143.26 1.47 1.04% |
Total Current Liabilities | First Reported 1985-12-31 | Previous Quarter 169.7 B | Current Value 165.6 B | Quarterly Volatility 39.9 B |
Check Novo Nordisk financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novo Nordisk's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.9 B, Interest Expense of 429.4 M or Selling General Administrative of 6.5 B, as well as many indicators such as Price To Sales Ratio of 14.16, Dividend Yield of 0.0178 or PTB Ratio of 30.85. Novo financial statements analysis is a perfect complement when working with Novo Nordisk Valuation or Volatility modules.
Novo | Total Current Liabilities |
Latest Novo Nordisk's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Novo Nordisk AS over the last few years. Total Current Liabilities is an item on Novo Nordisk balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Novo Nordisk AS are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Novo Nordisk's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novo Nordisk's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Novo Total Current Liabilities Regression Statistics
| Arithmetic Mean | 65,931,167,547 | |
| Geometric Mean | 43,931,457,597 | |
| Coefficient Of Variation | 81.02 | |
| Mean Deviation | 41,182,121,636 | |
| Median | 47,436,000,000 | |
| Standard Deviation | 53,420,449,001 | |
| Sample Variance | 2853744371.5T | |
| Range | 176.5B | |
| R-Value | 0.92 | |
| Mean Square Error | 468167064.5T | |
| R-Squared | 0.85 | |
| Slope | 10,997,767,527 | |
| Total Sum of Squares | 39952421200.9T |
Novo Total Current Liabilities History
About Novo Nordisk Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Novo Nordisk income statement, its balance sheet, and the statement of cash flows. Novo Nordisk investors use historical funamental indicators, such as Novo Nordisk's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Novo Nordisk investors may use each financial statement separately, they are all related. The changes in Novo Nordisk's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novo Nordisk's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novo Nordisk Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novo Nordisk. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 169.7 B | 178.1 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Novo Stock
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:Check out the analysis of Novo Nordisk Correlation against competitors. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.294 | Earnings Share 2.9 | Revenue Per Share 54.605 | Quarterly Revenue Growth 0.225 | Return On Assets 0.2524 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.